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Abstract
Background: The susceptibility of microbes such as Plasmodium falciparum to drugs is measured
in vitro as the concentration of the drug achieving 50% of maximum effect (IC50); values from a
population are summarized as geometric means. For antimalarial drugs, as well as for antibiotics,
assessing changes in microbe susceptibility over time under drug pressure would help inform
treatment policy decisions, but no standard statistical method exists as yet.
Methods: A mixed model was generated on loge-transformed IC50 values and calculated geometric
least squares means (GLSM) with 90% confidence intervals (CIs). In order to compare IC50s
between years, GLSM ratios (GLSMR) with 90%CIs were calculated and, when both limits of the
90%CIs were below or above 100%, the difference was considered statistically significant. Results
were compared to those obtained from ANOVA and a generalized linear model (GLM).
Results: GLSMRs were more conservative than ANOVA and resulted in lower levels of statistical
significance. The GLSMRs approach allowed for random effect and adjustment for multiple
comparisons. GLM was limited in the number of year-to-year comparisons by the need for a single
reference year. The three analyses yielded generally consistent results.
Conclusion: A robust analytical method can palliate inherent limitations of in vitro sensitivity
testing. The random effects GLSMRs with adjustment for multiple comparisons and 90%CIs require
only assumptions on the mixed model to be applied. Results are easy to display graphically and to
interpret. The GLMSRs should be considered as an option for monitoring changes in drug
susceptibility of P. falciparum malaria and other microbes.
Background
Plasmodium falciparum, the species causing most of the
malaria burden in the world, can be grown in culture,
which makes it possible to measure parasite drug suscep-
tibility in vitro [1]. Results are generally expressed as IC50
(the concentration achieving 50% of maximum effect).
Turnidge et al [2] presented a new method to evaluate cut-
off values to define antibacterial resistance. However,
while methodologies are well established for antimicrobi-
als [3], it is not possible, for the majority of drugs, to con-
fidently classify a strain as resistant or sensitive because
validated thresholds are not available, unlike the situation
with antibiotics [4].
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Of particular interest in P. falciparum drug susceptibility is
not the sensitivity profile of an isolate from a given
patient, but rather the monitoring of the sensitivity pat-
terns to drugs when submitted to drug pressure in a given
area [5]. This information may contribute to inform deci-
sion as to choice of drugs for the treatment of malaria.
However, evaluating trends over time poses methodolog-
ical problems, mainly because (i) the high variability of
results makes conventional statistical methods, such as
the analysis of variance (ANOVA), inadequate; (ii) the sta-
tistical unit is not the individual patient isolate but the
composite population of parasites within an individual.
Due to this distribution variability, these data are usually
presented as geometric mean. A key issue in the analysis
of these data is detecting trends over time. However, there
is still no standard statistical approach for this [6], with-
out loss of information.
Methods used in pharmacokinetic studies deal with simi-
lar problems in dealing with datasets with respect to drug
disposition in an individual or a population of individu-
als [7-9]. Bioequivalence between drug formulations is
typically assessed by using the analysis of variance of loge-
transformed data from a cross-over design with the null
hypothesis expressed by: H0: μT = μR where μT and μR rep-
resent the log-transformed expected bioavailability
parameters of the test and reference formulations respec-
tively [10,11]. A 90% confidence interval (CI) for the ratio
test/reference for bioavailability parameters is constructed
by using the equation:   where S is
the square root of the mean square error from the analysis
of variance, n is the number of subjects per period, t0.05(1)
is the critical value of t at α = 0.05 with υ the degrees of
freedom.
In the case of susceptibility testing conducted over time,
when subjects are grouped by the year of sampling, the
variance in the ANOVA of parasite susceptibility
(expressed as IC50) can be separated out into the contribu-
tions of the parasite, the subject and the time of measure-
ment. The ANOVA will allow for the year of measurement
and test whether the variability between years occurs at
random or not. The ratio of the mean sum of squares of
the parameter (e.g. IC50) to the error mean sum of squares
in the ANOVA will give an F-statistic to test the null
hypothesis: H0: μyear = μyear0. This will provide a test of
whether the arithmetic mean of IC50s measured from a
given year is identical to the mean of IC50s obtained in the
reference year.
An underlying assumption in order to use the ANOVA is
the normality of the residuals (the difference between an
individual value and the mean of the sample it belongs to,
xi -  .) However, verifying the null hypothesis of identity
between means may not be possible with distributions of
residuals that are generally neither normal nor log-nor-
mal. Furthermore, the sample size is most often too small
with respect to the variance for the comparison of means.
The high variability of data leads to large error variability
in terms of error sum of squares. Thus, the detection of a
difference will be difficult to interpret since it will be a
function of the variability of data and sample size for each
year. Mixed models can be used when there are different
levels of clustering in the observations. One can assume
that there is a grouping per year and a random part of
measurements within years due to the subject and the par-
asites strains the subject is infected with. It allows the user
to analyse samples (here: years) with unequal sample
sizes and to relax the assumption of independently and
identically distributed residuals while accounting for the
data structure in a more flexible way [12].
For malaria, with the introduction of new treatment regi-
mens such as the Artemisinin-containing Combination
Therapies (ACTs) [13], it is important to evaluate whether,
with parasites being exposed to drug pressure, the
amounts of drug needed to inhibit parasite growth
departs from that of a reference year, prior to and during
deployment to monitor the evolution of drug susceptibil-
ity. In addition, appropriate statistical methods are
needed to account for the variability in the determination
of IC50s in order to properly inform treatment policy deci-
sions.
Several approaches were explored to describe the trends
over time of parasite in vitro drug susceptibility of the par-
asite using a dataset collected in Casamance (south-west-
ern Senegal) during 2000–2004 slightly adapted for the
purpose from Agnamey et al [14].
Methods
Mixed model
A fixed effect model can be expressed as yij = μ + tj + eij
where j is the year of measurement, yij the observation on
year j for patient I, μ the overall mean (also referred to as
intercept in statistical softwares), tj the relative effect of
year j, μ + tj is the mean effect for the year j and eij the resid-
ual variance for year j on the ith patient[12]. The model
allows for the patient effect, in which case the formula
becomes yij = μ + pi+ tj + eij where pi represents the ith
patient effect. Instead of defining some effects as constants
in the model, one could consider them as arising from
independent samples with a normal distribution[12], i.e.
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as random effects. The model containing both fixed and
random effects can then be referred to as a mixed model
[12,15]. The underlying assumptions to using mixed
models are: normally distributed residuals, normally dis-
tributed random effects and residuals independent of the
random effects.
GLSMRs calculations
A mixed linear model of loge-transformed values was esti-
mated whereby the year was considered as fixed and the
intercept as a random effect. The isolates were from differ-
ent subjects each year.
From the mixed model, t statistics of standardized pair
wise differences were calculated as   where i and j
are the indices of two years,   and   are the least square
means (LSM) for years i and j and   is the square-root
of the estimated variance of  . In this model, LSMs
are predicted population means from loge-transformed
values. Consequently, assuming that
 and that the geometric mean is
the antilog of the mean of loge-transformed values, the
geometric least squares means ratio (GLSMR) can be cal-
culated with the antilog of the   (LSMs differences)
extracted from the model (where yi and yj can be expressed
as linear combination li'b and lj'b of the parameter esti-
mates). From these linear combinations the parameter
estimates that define the LSMs,  , (i.e. the standard
deviation of the LSMs difference), can be estimated by
. The confidence interval can be derived
as .
GLSM ratios (GLSMRs) were calculated for each between-
year comparison. An adjustment for multiple compari-
sons was done in order to control for the overall type 1
error rate using the Tukey-Kramer method (chosen
because it allows for unequal sample size between years).
GLSMRs were considered statistically different if both
bounds of the CIs fell on either side of the value of 1 (or
100% in percentage values). Previously [14], we had used
GLSMRs calculated without this adjustment and evalu-
ated the 95%CIs.
Standard statistical methods
Standard methods such as the one-way ANOVA were also
used with the year as fixed factor to analyse the variations
of IC50s over time. For non-normally distributed data (sig-
nificant Kolmogorov-Smirnov test), a loge-transformation
was applied. The Levene test for homogeneity of the vari-
ance was used and, in case of non-homogeneity, a Welch
adjustment for the ANOVA. A non-parametric Kruskall-
Wallis sign rank test was used when parametric analyses
were not suitable. Pair-wise mean comparisons between
years for each treatment were carried out following
ANOVA with a Tukey adjustment. Normality of residuals
was checked with a non significant Shapiro-Wilk test and
normal probability plots. Concurrently a generalized lin-
ear model (GLM) was also estimated with the year as fixed
factor using a normal probability function and an identity
link function parameterization [16].
A p-value of < 0.05 was considered statistically significant.
All tests were two-tailed. Statistical analyses were carried
out with the statistical package SAS® System version 9.1.3
(SAS Institute, Cary, NC, USA).
Dataset
The dataset is an update of the one described in Agnamey
et al [14]. Briefly, in vitro susceptibility of local isolates to
chloroquine (CQ), quinine (QN), artemisinin (ART) and
the amodiaquine metabolite monodesethylamodiaquine
(MdAQ) were monitored the using the DELI test [17]
before (1997) and during the deployment (2000–2004)
of artesunate+amodiaquine combination in Mlomp, a vil-
lage in the district of Oussouye in Casamance, Southern
Senegal, where malaria is mesoendemic (25 infective
bites/person-year) and transmission occurs year-round
with a peak during the rainy season (July–December).
Samples for the in vitro assay were from consecutive
patients recruited as part of an observational study [18]
with a P. falciparum mono-infection and parasitaemia ≥
0.2% [19].
Results
IC50s from 242 subjects for CQ, 250 subjects for QN, 236
subjects for MdAQ and 183 subjects for ART were used in
these statistical analyses [14]. The number of subjects with
in vitro results was different among years and products
tested (Table 1). Means with two standard deviations
along with data distributions are plotted in Figure 1.
Mean, Geometric means and GLSMs are presented
together in Table 1. For all products except log-trans-
formed ART, values were not normally distributed (Kol-
mogorov-Smirnov test p < 0.05).
Results of the analyses using the different methods
The ANOVA pair wise means comparisons (Table 2)
showed no significant differences for CQ IC50 values. For
MdAQ, statistically significant increases were observed
between 1997 and 2000–2004, while there were decreases
in IC50s between 2000–2004, 2001–2004 and
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2002–2004. For QN, a statistically significant increase was
observed between 1997 and 2001, and a decrease between
2001–2002 and 2001–2004 (Figure 1). For ART, no statis-
tically significant differences were observed.
Using the GLM with 1997 as the reference year (Table 3),
no relationship was found for CQ and ART, a significant
positive estimate for MdAQ (IC50s decreased) and a signif-
icant positive estimate for QN in 2001, followed by a neg-
ative estimate (IC50s increased) in 2002.
GLSMR (Table 4) of CQ IC50s showed no significant dif-
ferences, consistent with a stable response to CQ over the
study period (Figure 2). For MdAQ, there were statistically
significant increases between 1997 and 2000–2004. From
2000 to 2004, there was a decrease in IC50s which was sig-
nificant between 2000 and 2004, 2001 and 2004, as well
as 2002 and 2004. QN showed an increase between 1997
and 2001 and 2001–2002, and a significant decrease
between 2002–2004. For ART, no statistically significant
changes were found (Figure 2).
Comparison of the results obtained with the different 
methods used
GLSMRs and ANOVA generated consistent results. With
the GLM, results were similar to the two other tests for CQ
and ART; for MdAQ, the GLM identified only a decrease
between 1997 and 2001; for QN, it showed an increase
between 1997 and 2001, while the ANOVA and GLSMRs
revealed a decrease for 2001–2002 and 2001–2004 peri-
ods respectively.
For comparison, when this set of data is analysed with
GLSMRs with no random intercept and 95%CIs calcu-
lated without adjustment for multiple comparisons,
results are slightly different from the current GLSMRs.
With the former, significant differences are found for
1997–2000 for CQ and ART, between 2001–2002 for CQ
and 2002–2003 for ART. There are two significant differ-
ences with 2000 as reference year in comparison with
2002 and 2004, which are not found with the current
GLSMRs. Similarly, 2001 is different from 2003 and 2003
from 2004. In the case of ART, the year 2003 is signifi-
cantly different from the others while it was not with the
current GLSMRs
Discussion
In this study, three different statistical methods to assess
changes of IC50 over time (ANOVA, GLM, GLSMRs) were
compared. The use of data from a single site of moderate
to high transmission (25 infecting bites per person-year),
and with consistent treatment policies and practices,
meant that all patients were expected to be infected with
parasites having been under the same degree of drug pres-
sure.
Table 1: Means of raw and loge-transformed IC50s, geometric means and Geometric Least Squares Means.
1 9 9 7 2 0 0 02 0 0 12 0 0 22 0 0 32 0 0 4 N o r m a l i t y
Variable N Mean STD N Mean STD N Mean STD N Mean STD N Mean STD N Mean STD p-value
Means (raw values)
CQ 31 236 203.4 33 173.2 223 31 251.4 236.7 46 131.3 104 34 143.8 91.03 67 171.5 157.2 0.01
QN 46 234.6 150.2 28 305.8 210.4 31 444 286.2 40 252.6 273.6 34 280.8 162.8 58 207.5 149.8 0.01
MdAQ 45 12.8 12.4 33 85.1 167.8 31 57.7 63.2 43 42.9 32.3 34 31.1 21.3 64 21.7 17.6 0.01
ART 10 3.6 0.8 31 9.8 12.0 31 6.1 6.6 40 5.7 4.5 34 7.4 5.9 36 7.5 5.0 0.01
Means (natural log values)
CQ 31 4.9 1.4 33 4.4 1.2 31 5 1.2 46 4.5 0.9 34 4.7 0.8 67 4.7 1 0.01
QN 46 5.2 0.8 28 5.5 0.8 31 5.9 0.7 40 5.1 0.9 34 5.5 0.5 58 5.1 0.8 0.04
MdAQ 45 2.1 0.9 33 3.8 1.0 31 3.6 0.9 43 3.5 0.7 34 3.2 0.6 64 2.8 0.9 0.04
ART 10 1.2 0.3 31 1.8 1.0 31 1.3 1 40 1.3 1.0 34 1.8 0.6 36 1.8 0.7 0.15
Geometric means
CQ 31 130.3 3.9 33 82.3 3.5 31 148.4 3.2 46 93.7 2.5 34 112.2 2.2 67 115.6 2.7 -
QN 46 181.3 2.3 28 237.5 2.2 31 350.7 2.1 40 169.0 2.6 34 244.7 1.7 58 162.4 2.1 -
MdAQ 45 8.5 2.5 33 43.8 2.7 31 38.5 2.4 43 33.1 2.1 34 25.3 1.9 64 15.8 2.4 -
A R T1 03 . 5 1 . 33 15 . 8 2 . 73 13 . 9 2 . 74 03 . 9 2 . 83 46 . 1 1 . 93 66 . 0 2 . 0 -
Geometric Least Squares Means
CQ 31 130.8 1.2 33 82.6 1.2 31 148.4 1.2 46 93.3 1.2 34 112.7 1.2 67 115 1.1 -
QN 46 181.3 1.1 28 238.2 1.2 31 350.1 1.1 40 168.4 1.1 34 245 1.1 58 162.2 1.1 -
MdAQ 45 8.5 1.1 33 44 1.2 31 38.5 1.2 43 33.1 1.1 34 25.3 1.2 64 15.9 1.1 -
A R T1 03 . 5 1 . 33 15 . 8 1 . 23 13 . 9 1 . 24 03 . 9 1 . 13 46 . 1 1 . 23 66 . 0 1 . 1 -
P-values are from the Kolmogorov-Smirnov test for normality. CQ = chloroquine; QN = quinine; MdAQ = monodesethylamodiaquine; ART = 
artemisininMalaria Journal 2007, 6:156 http://www.malariajournal.com/content/6/1/156
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Normality assumption
Data were not normally distributed, even after loge-trans-
formation, for all drugs except loge-transformed ART. The
ANOVA can be used on non-normally distributed values
(although in this case conclusions are less robust), and
allows for multiple pair wise comparisons adjustment
(but then residuals must be checked for independence
and normality as well as homosedasticity, i.e the condi-
tion whereby variances are equal.) The GLM requires nor-
mally distributed values when using an identity link
function (i.e. an assumption of normal distribution for
the studied parameter) for comparison with a unique ref-
erence (baseline) value. For non-normally distributed
data, a different model must be used for each different ref-
erence value of the independent factor. The GLSMRs
approach can use non normally distributed values and
allows adjusted multiple comparisons between years.
GLSMR
The GLSMR had broader applicability than the other
methods because, even if a mixed model is used to obtain
the LSMs, it does not require either normally distributed
IC50s or variance homogeneity. However, one needs to
verify the assumptions needed for a mixed model such as
the normality of the residuals, the normality of the ran-
dom effects, and the independence of the residuals and
the random effects. As loge-transformation serves the pur-
pose of deriving GLSMs of the results, the linear mixed
Scatterplots of the loge-transformed values of the quinine (QN), chloroquine (CQ), monodesethylamodiaquine (MdAQ), and  artemisinin (ART) IC50s between years Figure 1
Scatterplots of the loge-transformed values of the quinine (QN), chloroquine (CQ), monodesethylamodiaquine (MdAQ), and 
artemisinin (ART) IC50s between years. The straight line is the cut-off value for susceptibility to the products (here: 100 nM for 
CQ, 60 nM for AQ, 500 nM for QN and 15 nM for ART [4]). The means of each year are connected with a trend line. The box 
around each year distribution of values represent two standard deviation of the mean.M
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Table 2: Pairwise Least Squares Means comparisons following ANOVA of chloroquine (CQ), monodesethylamodiaquine (MdAQ), Quinine (QN) and Artemisinin (ART) loge-
transformed IC50 (nM) between years.
MdAQ CQ QN ART
year Comparison Difference 
Between Means
Simultaneous 95% 
Confidence Limits
Sig. Difference 
Between Means
Simultaneous 95% 
Confidence Limits
Sig. Difference 
Between Means
Simultaneous 95% 
Confidence Limits
Sig. Difference 
Between Means
Simultaneous 95% 
Confidence Limits
Sig.
1997 – 2000 -1.6 -2.3 -1.0 *** 0.5 -0.4 1.4 -0.3 -0.9 0.4 -0.5 -1.6 0.5
1997 – 2001 -1.5 -2.2 -0.8 *** -0.1 -1.0 0.8 -0.7 -1.3 0.0 *** -0.1 -1.2 0.9
1997 – 2002 -1.4 -2.0 -0.7 *** 0.3 -0.5 1.2 0.1 -0.5 0.6 -0.1 -1.1 0.9
1997 – 2003 -1.1 -1.7 -0.4 *** 0.1 -0.7 1.0 -0.3 -0.9 0.3 -0.6 -1.6 0.5
1997 – 2004 -0.6 -1.2 -0.1 *** 0.1 -0.6 0.9 0.1 -0.4 0.6 -0.5 -1.6 0.5
2000 – 1997 1.6 1.0 2.3 *** -0.5 -1.4 0.4 0.3 -0.4 0.9 0.5 -0.5 1.6
2000 – 2001 0.1 -0.6 0.8 -0.6 -1.5 0.3 -0.4 -1.1 0.3 0.4 -0.3 1.1
2000 – 2002 0.3 -0.4 0.9 -0.1 -0.9 0.7 0.3 -0.3 1.0 0.4 -0.3 1.1
2000 – 2003 0.6 -0.1 1.2 -0.3 -1.2 0.6 0.0 -0.7 0.6 -0.1 -0.8 0.7
2000 – 2004 1.0 0.4 1.6 *** -0.3 -1.1 0.4 0.4 -0.2 1.0 0.0 -0.7 0.7
2001 – 1997 1.5 0.8 2.2 *** 0.1 -0.8 1.0 0.7 0.0 1.3 *** 0.1 -0.9 1.2
2001 – 2000 -0.1 -0.8 0.6 0.6 -0.3 1.5 0.4 -0.3 1.1 -0.4 -1.1 0.3
2001 – 2002 0.2 -0.5 0.8 0.5 -0.4 1.3 0.7 0.1 1.4 *** 0.0 -0.7 0.7
2001 – 2003 0.4 -0.3 1.1 0.3 -0.6 1.2 0.4 -0.3 1.0 -0.5 -1.2 0.3
2001 – 2004 0.9 0.3 1.5 *** 0.3 -0.5 1.0 0.8 0.2 1.4 *** -0.4 -1.2 0.3
2002 – 1997 1.4 0.7 2.0 *** -0.3 -1.2 0.5 -0.1 -0.6 0.5 0.1 -0.9 1.1
2002 – 2000 -0.3 -0.9 0.4 0.1 -0.7 0.9 -0.3 -1.0 0.3 -0.4 -1.1 0.3
2002 – 2001 -0.2 -0.8 0.5 -0.5 -1.3 0.4 -0.7 -1.4 -0.1 *** 0.0 -0.7 0.7
2002 – 2003 0.3 -0.4 0.9 -0.2 -1.0 0.6 -0.4 -1.0 0.2 -0.5 -1.1 0.2
2002 – 2004 0.7 0.2 1.3 *** -0.2 -0.9 0.5 0.0 -0.5 0.6 -0.4 -1.1 0.2
2003 – 1997 1.1 0.4 1.7 *** -0.1 -1.0 0.7 0.3 -0.3 0.9 0.6 -0.5 1.6
2003 – 2000 -0.6 -1.2 0.1 0.3 -0.6 1.2 0.0 -0.6 0.7 0.1 -0.7 0.8
2003 – 2001 -0.4 -1.1 0.3 -0.3 -1.2 0.6 -0.4 -1.0 0.3 0.5 -0.3 1.2
2003 – 2002 -0.3 -0.9 0.4 0.2 -0.6 1.0 0.4 -0.2 1.0 0.5 -0.2 1.1
2003 – 2004 0.5 -0.1 1.1 0.0 -0.8 0.7 0.4 -0.2 1.0 0.0 -0.7 0.7
2004 – 1997 0.6 0.1 1.2 *** -0.1 -0.9 0.6 -0.1 -0.6 0.4 0.5 -0.5 1.6
2004 – 2000 -1.0 -1.6 -0.4 *** 0.3 -0.4 1.1 -0.4 -1.0 0.2 0.0 -0.7 0.7
2004 – 2001 -0.9 -1.5 -0.3 *** -0.3 -1.0 0.5 -0.8 -1.4 -0.2 *** 0.4 -0.3 1.2
2004 – 2002 -0.7 -1.3 -0.2 *** 0.2 -0.5 0.9 0.0 -0.6 0.5 0.4 -0.2 1.1
2004 – 2003 -0.5 -1.1 0.1 0.0 -0.7 0.8 -0.4 -1.0 0.2 0.0 -0.7 0.7Malaria Journal 2007, 6:156 http://www.malariajournal.com/content/6/1/156
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model allowed to relax the assumption of independence
of the model residuals and to account for the inherent var-
iability of the data structure in a more flexible way. The in
vitro test reflects the susceptibility of the whole parasite
population in one isolate, and thus cannot separate the
effects of the various parasite clones in a given infected
subject. Therefore one cannot parameterize the within-
subject effect or within-parasite population effect in the
linear mixed model. However, it can be argued that these
effects are taken into account in the overall mean, which
was defined as random in the model.
GLSMRs calculated at a 5% level without an adjustment
for multiple comparisons are more likely to wrongly
detect a significant difference because of the multiplicity
of the statistical tests performed than the GLSMRs at a 1%
level and with an adjustment for multiplicity.
Linear models
ANOVA and pair wise means comparisons between years
were good indicators of a difference between years. Note-
worthy, in bioequivalence studies GLSMR are generally
computed using an ANOVA model, but effects specified as
random in a linear model are treated as a fixed factor as
they serve the sole purpose of producing the correspond-
ing expected mean squares [20]. These expected mean
squares lead to the traditional ANOVA components with-
out accounting for the random effect in the variance.
In the GLSMRs calculations, the mixed linear model was
computed using restricted maximum likelihood to evalu-
ate variance parameters, which are in general preferred to
ANOVA estimates [20]. Furthermore, mixed models are
commonly used when there are different levels of cluster-
ing in the observations. The sole level of grouping was the
year (treated as fixed in the model), so no other particular
variable (or grouping level) was defined as random. The
reasons for treating the time variable as discrete (i.e. by
calendar year and not as a continuous variable) are: (i)
there was a 3-year gap between 1997 (the baseline) and
2000 (the first of a series of five consecutive years.); (ii)
only qualitative or discrete variables allowed for the
model to simply extract estimates for the different catego-
ries of the year effect; (iii) the majority of malaria cases
and treatments cluster between July–November during
the wet season. Hence, subjects were grouped by year and
it was assumed that there was a random part of measure-
ments within years due to the contribution of the subject
and the parasite strains subjects were infected with. Specif-
ically, the number of isolates for each year was not the
same and IC50s varied considerably from year to year
(Table 1).
The GLM appears not to be suitable to compare IC50s
because it treated values as if there were repeat measures
from the same subjects, while isolates came from different
individuals. In addition, IC50s were non-normally distrib-
uted despite loge-transformation.
Estimates of the IC50
It is clear that customary approaches are not satisfactory as
the difficulty in the analyses is that the data are not time
series or longitudinal data. They are also not normally dis-
tributed – a necessary condition to use parametric statisti-
cal tests, and a critical point of this work. In a recently
published paper, Kaddouri et al [21] developed a new
inhibitory sigmoid Emax statistical model to estimate
more precisely the IC50 of a given subject. However, it
requires cut-off values for resistance of the studied para-
sites strains to a range of treatment, an element which is
not easy to derive for antimalarial drugs. A Bayesian
approach was also proposed recently to provide a correc-
tion of the estimate of the true IC50 [22]. This work was
based on the assumption that resistance is systematically
overestimated because: (i) the precision of the estimated
IC50 value of the most resistant isolate will usually be the
poorest of all the isolates assayed, (ii) sigmoid curve fit-
ting or probit analysis of a unique isolate takes no account
of other isolates in the series tested. This approach
requires the distribution of measured IC50 to be estab-
Table 3: Generalized linear model (SAS System Proc Genmod) of chloroquine (CQ), monodesethylamodiaquine (MdAQ), quinine 
(QN) and artemisinin (ART) IC50 (nM) with the year as independent parameter (loge-transformed values and 1997 as the reference 
value).
CQ MdAQ QN ART
Parameter Estimate Std Error p Estimate Std Error p Estimate Std Error p Estimate Std Error p
Intercept 4.9 0.2 <.0001 2.1 0.1 <.0001 5.2 0.1 <.0001 1.2 0.3 <.0001
year* 2000 -0.5 0.3 N.S. 1.6 0.2 <.0001 0.3 0.2 N.S. 0.5 0.3 N.S.
2001 0.1 0.3 N.S. 1.5 0.2 <.0001 0.7 0.2 0.0003 0.1 0.3 N.S.
2002 -0.3 0.2 N.S. 1.4 0.2 <.0001 -0.1 0.2 N.S. 0.1 0.3 N.S.
2003 -0.1 0.3 N.S. 1.1 0.2 <.0001 0.3 0.2 N.S. 0.6 0.3 N.S.
2004 -0.1 0.2 N.S. 0.6 0.2 0.0001 -0.1 0.2 N.S. 0.5 0.3 N.S.
Scale 1.1 0.0 - 0.8 0.0 - 0.8 0.0 - 0.8 0.0 -M
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Table 4: IC50s for chloroquine (CQ) quinine (QN), monodesethylamodiaquine (MdAQ) and artemisinin (ART) in nM. Geometric Least Squares Means Ratio between years.
MdAQ CQ QN ART
Variable 2 one-sided 
90% limits
GLS Mean 
Ratio (%)
90%CI 2sided t p-value GLS Mean 
Ratio (%)
90%CI 2sided t p-value GLS Mean 
Ratio (%)
90%CI 2sided 
t-value
GLS Mean 
Ratio (%)
90%CI 2sided t p-value
1997 vs 2000 [80,125] 516.7 [266.4,1002.3] <0.0001 63.2 [25.5,156.7] N.S. 131.4 [69.3,249.2] N.S. 166.8 [57.2,486.0] N.S.
1997 vs 2001 [80,125] 452.3 [230.3,888.2] <0.0001 113.5 [45.1,285.4] N.S. 193.1 [103.8,359.2] 0.005 110.9 [38.0,323.0] N.S.
1997 vs 2002 [80,125] 388.2 [209.6,719.2] <0.0001 71.3 [30.7,165.8] N.S. 92.9 [52.1,165.4] N.S. 110.8 [39.2,313.4] N.S.
1997 vs 2003 [80,125] 297.1 [154.0,573.0] <0.0001 86.2 [35.0,212.3] N.S. 135.1 [73.9,247.2] N.S. 175.6 [61.0,505.7] N.S.
1997 vs 2004 [80,125] 186.3 [106.1,326.9] 0.003 88.0 [40.0,193.5] N.S. 89.5 [52.8,151.6] N.S. 172.5 [60.3,493.5] N.S.
2000 vs 2001 [80,125] 87.5 [42.5,180.4] N.S. 179.6 [72.4,445.3] N.S. 147.0 [73.3,294.9] N.S. 66.5 [31.5,140.3] N.S.
2000 vs 2002 [80,125] 75.1 [38.5,146.7] N.S. 112.9 [49.3,258.3] N.S. 70.7 [36.6,136.5] N.S. 66.4 [32.9,134.2] N.S.
2000 vs 2003 [80,125] 57.5 [28.4,116.5] N.S. 136.4 [56.1,331.1] N.S. 102.9 [52.0,203.3] N.S. 105.3 [50.7,218.5] N.S.
2000 vs 2004 [80,125] 36.1 [19.4,67.0] <0.0001 139.2 [64.3,301.2] N.S. 68.1 [36.8,125.9] N.S. 103.4 [50.3,212.5] N.S.
2001 vs 2002 [80,125] 85.8 [43.4,169.6] N.S. 62.8 [27.0,146.1] N.S. 48.1 [25.4,91.1] 0.002 100.0 [49.4,202.0] N.S.
2001 vs 2003 [80,125] 65.7 [32.0,134.7] N.S. 75.9 [30.8,187.0] N.S. 70.0 [36.0,135.8] N.S. 158.4 [76.3,328.7] N.S.
2001 vs 2004 [80,125] 41.2 [21.9,77.5] 0.000 77.5 [35.2,170.5] N.S. 46.3 [25.6,83.9] <0.0001 155.6 [75.7,319.8] N.S.
2002 vs 2003 [80,125] 76.5 [39.4,148.6] N.S. 120.8 [53.2,274.6] N.S. 145.5 [78.0,271.2] N.S. 158.5 [79.8,314.7] N.S.
2002 vs 2004 [80,125] 48.0 [27.1,84.8] <0.0001 123.3 [61.5,247.2] N.S. 96.3 [55.7,166.8] N.S. 155.7 [79.2,305.9] N.S.
2003 vs 2004 [80,125] 62.7 [33.9,115.8] N.S. 102.1 [47.5,219.2] N.S. 66.2 [37.2,117.9] N.S. 98.2 [48.6,198.4] N.S.Malaria Journal 2007, 6:156 http://www.malariajournal.com/content/6/1/156
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lished before using it to produce a large number of points
and estimate the median as the true IC50. In doing so, one
is inevitably faced with the problem of normality and the
choice to apply data transformations such as log or Box-
Cox [23]. This work offers an alternative way to deal with
data transformation and normality condition in the con-
text of the evolution of microbial susceptibility to drugs.
Expression of results
GLSMRs were found to be more intuitive, as results are
expressed as percentage difference (increase or decrease)
between two years, while with LSMs comparisons
increases and decreases from the reference appear as
inverted (they are marked with a negative and a positive
sign, respectively). As geometric means are generally used
to express IC50s of a pool of isolates, GLSMR are naturally
easier to understand and interpret than the other statisti-
cal methods tested here.
Two different plots were also produced in order to illus-
trate the difficulties in interpreting trends over time in
drug susceptibility. Figure 1 is a traditional way of plotting
the distribution of IC50s with cut-off values above which a
strain is resistant to a given drug. This makes the reader
falsely interpret means against the cut-off, while there is a
great variability in the data and no validated thresholds
for the majority of antimalarial drugs. In addition, this
display does not provide any indication of the signifi-
cance (or lack thereof) of change between years. Figure 2
is based on the GLSMR results and provides a direct com-
Geometric Least Squares Means Ratios of the IC50s to quinine (QN), chloroquine (CQ), monodesethylamodiaquine (MdAQ),  and artemisinin (ART) Figure 2
Geometric Least Squares Means Ratios of the IC50s to quinine (QN), chloroquine (CQ), monodesethylamodiaquine (MdAQ), 
and artemisinin (ART). The legend indicates the reference year for the ratio. The x-axis indicates the year tested in the ratio. A logarith-
mic scale was applied for QN.
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parison of GLSM between years; it does not need the cut-
off values; it depicts visually a statistical test as the confi-
dence intervals of each GLSMR against the line of identity
between sets of data (here: years).
Conclusion
Treatment policy decisions would benefit from reliable
information on changes in susceptibility of parasite or
bacterial isolates to drugs over time. This entails an ade-
quate statistical method, which can also account for the
inherent variability of in vitro drug susceptibility tests
(Figure 2). This is particularly important for antimalarial
drugs and cases alike where validated thresholds for resist-
ance are not available. The underlying linear mixed model
of GLSMRs allowed accounting for this variability and for
unequal number of isolates collected during field testing.
Based on these data GLSMRs appear to be more accurate
and to offer advantages over other tests for the "longitudi-
nal" analysis of IC50s. We used a simple statistical model
which produces easily interpretable results and can be
found in any statistical software. Finally, the utility of
GLSMRs in monitoring drug susceptibility of not only
malaria parasites but also other microbes should be fur-
ther tested.
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